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Introduction
Tumor heterogeneity [1-4] is an old concept but its
impact on the cancerogenesis process is poorly under-
stood. Breast cancer is a noteworthy model for its fre-
quency, and for the diversity of its phenotypes and of its
evolution. This study examines the influence of the het-
erogeneity of tumor proliferation on disease-free survival
of patients with a breast carcinoma.
Material and methods
Histological slides
The study involved a series of 368 patients from the Fran-
çois Baclesse Cancer Centre (Caen) treated for a breast
carcinoma between 1991 and 1995, whitout neoadjuvant
therapy and with a follow-up of more than 15 years. The
table 1 contains the description of the series.
Histological sections, representative of each tumor,
have been stained with the anti-phosphohistone-H3
antibody (PHH3: Ser10, MILLIPORE®, dilution 1/600)
[5,6]. With this specific immuno-stain, cells presenting
mitosis figures are more easily identifiable (Figure 1).
Acquisition
Histological slides have been scanned with a high reso-
lution slide scanner to obtain virtual slides with a final
resolution of 0.5 µm (ScanScope® CS from Aperio
Technologies (20x NA 0.7 objective). The true color
images obtained (color RGB 24 bits) have been saved in
the tiled pyramidal TIFF file format.
Region of interest (ROI)
Before the automatic image analysis, the user can dis-
card “normal” tissue surrounding the tumor by drawing
a region of interest on the high resolution virtual slide
with the Aperio ImageScope® software.
Image processing
The image processing was performed in two steps on a
personal computer with a 1.6 GHz Pentium IV proces-
sor and a 1 GB of random access memory (RAM). The
first step being a sub-sampling of virtual slide done with
a specific algorithm ‘Daubechies’ second moment ortho-
gonal wavelet decimation developed in C++ language
which creates a low resolution image of the virtual slide
(divided by 8: from 0.5µm to 4µm/pixels). In a second
step, the low resolution image is automatically processed
thanks to chaining operators of image analysis toolbox
software (Aphelion, ADCIS).
In addition to estimating the frequency of mitotic fig-
ures, the program detects “hot spots” and measures 9 fea-
tures representing the tumor heterogeneity, including the
Haralick texture features and Fisher’s index. The zones of
influence of each stained nuclei have been determined
using Voronoï’s pavement principle. When nuclei are
close, the size of pavements is small, highlighting the
“hot spots”.
Feature selection
A principal component analysis has been done in order
to select the most relevant features.
Statistic analysis
These features have been statistically analyzed, com-
bined with classic clinic-pathological prognostic factors
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(age, tumor size, grading, mitotic index, vascular emboli
and metastatic lymph nodes).
Results
Principal component analysis
Thanks to the principal component analysis (PCA) 4
features representing tumor heterogeneity have been
chosen then combined into three new features: CP1,
CP2 and CP3, corresponding to the three principal
directions of the PCA.
The four selected features are:
- 2 Haralick’s texture indexes (correlation and energy);
- Fisher’s index;
- variance of the size of Voronoï pavements.
The variance of the size of Voronoï pavement (named
Voronoï) and the Fisher’s index are regional features
whereas the Haralick’s texture indexes are local features.
Indeed, Voronoï and Fisher features are “cutting” the
tissue into pieces and analyzing each of them compared
to the others, whereas Haralick is dealing with relations
between neighbor pixels, each pixel representing a cell
at this resolution.
Prognostic study
In the analysis of prognostic factors, disease free survival
was used as the end point.
Univariate statistical analysis (DFS)
Univariate analysis of disease free survival was per-
formed with the features of age, tumor location, initial
tumor size, pathologic lymph node status (N), histologi-
cal type, SBR grade, mitotic index, vascular emboli,
metastatic lymph nodes and hormone receptor status.
The results are shown in Table 1 for usual features, in
Table 2 for heterogeneity features.
The CP2 feature correlated highly with disease free
survival, whereas the variance of the Voronoï pavements
was borderline significant.
Multivariate statistical analysis (Cox)
The above features that correlated with disease free
survival in univariate analysis were combined with
Figure 1 dyes used to stain the histological sections. a: histological slide stained with HES; b: histological slide of the same case
immunohistochemically stained with PHH3 [6-8] (anti-phosphohistone-H3 antibody); c: thanks to this specific immunohistochemical,
identification of cells with mitosis figures, from prophase to telophase, is improved.
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clinic-pathologic factors and included in the multivariate
analysis. Cox’s regression analysis highlighted 3 indepen-
dent prognostic factors: tumor heterogeneity feature CP2
(RR = 1.46; p = 0.03), mitotic index (RR = 1.71; p =
0.004) and lymph node metastasis (RR = 2.20, p <
0.0001) correlated highly with disease free survival.
The construction of this model has individualized
3 groups of patients: 0 factor, 1 or 2 factors and 3 poor
prognostic factors (mitotic index > 10, lymph node
metastasis in the axillary dissection, upper tercile of
CP2; p < 0.0001).
Disease free survival according to this model is shown
in Figure 2.
Discussion and conclusion
To characterize tumor heterogeneity in the presented
series of breast cancer, 9 features were computed. 4 non-
redundant of them have been selected by principal com-
ponent analysis (PCA).
PCA was also used to create 3 new composite fea-
tures: CP1, CP2 and CP3, corresponding to the 3 princi-
pal directions of the PCA.
The univariate analysis made for each feature from
image analysis has first highlighted that only the combi-
nation CP2 and Voronoï’s feature had a prognostic
value. It has to be noted that a high value of heteroge-
neity index is associated with a poor prognosis.
In multivariate analysis, CP2 was found to be an inde-
pendent prognostic feature just like the mitotic index
and the lymph node status. The lymph node status is a
well-known clinical factor; the two other features are
intrinsic factors of tumor growth, at cellular level for
mitotic index and at the tissue level for heterogeneity.
Surprisingly, age, tumor size, Scarff and Bloom Grade
and hormone receptor status are of secondary impor-
tance compared to these 3 features.
This result encourages to confront the heterogeneity
feature CP2 to clinic information, such as recent or late
oncologic event or the nature locoregional or distant
visceral of the recurrence, and to the absence of lymph
node metastasis.
Table 1 Univariate Analysis of Disease Free Survival –
368 Eligible Patients. In grey: Follow up (2011)
Variable No. of patients P value
Age





Right breast 176 (47.8%)
Left breast 187 (50.8%)
Synchronous bilateral 5 (01.4%)
Tumor size













Grade 1 50 (14%)
Grade 2 180 (49%) 0.002
Grade 3 137 (37%)
Mitotic index (/1.7mm²)





Yes 153 (44%) <0.0001
No 195 (56%)
Hormone receptor status (at least 1)
Yes 265 (73%) 0.030
No 98 (27%)












Table 2 Results of the univariate analysis
Variables P value
Voronoï 0.040
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